PENG Xiao-yan 1LUAN Yi 1YANG Ji-cao1
作者信息
- 1. Nanyang Second People's Hospital,Nanyang 473000,China
- 折叠
摘要
Abstract
Objective:To investigate the effects of sacubitril/valsartan on changes in cardiac function and the risk of major adverse cardiovascular events(MACE)in patients with coronary heart disease.Methods:A total of 278 patients with newly diagnosed coronary heart disease at a hospital between January 2023 and February 2024 were selected and assigned to the control group(n=100)and study group(n=178)in a 2:1 ratio using random number table method.Both groups received conventional therapy.In addition to conventional therapy,the control group was treated with enalapril maleate tablets,while the study group was treated with sacubitril valsartan sodium tablets.Both groups received continued treatment and were followed up for 1 year.The hemodynamic parameters[systolic blood pressure(SBP),diastolic blood pressure(DBP),heart rate(HR),cardiac output(CO)],cardiac structure and function indices[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)]before treatment and after 3 and 6 months of treatment were compared between the two groups.The difference in MACE incidence over the 1-year follow-up was also analyzed.Logistic regression analysis with forward stepwise selection was performed to determine whether sacubitril/valsartan was an independent influencing factor for the occurrence of MACE in patients with newly diagnosed coronary heart disease.Results:After 3 and 6 months of treatment,SBP,DBP,LVEDD and LVESD decreased in both groups,with the study group showing lower values than the control group(P<0.05).LVEF increased in both groups,with the study group showing higher values than the control group(P<0.05).During follow-up,the MACE incidence in the study group(8.4%)was lower than that in the control group(18.0%,χ2=5.609,P=0.018).After adjusting for factors such as gender,age,hypertension and diabetes mellitus,Logistic regression analysis indicated that the use of sacubitril/valsartan was an independent protective factor against MACE in patients with newly diagnosed coronary heart disease(OR=0.414,95%CI 0.198～0.866,P=0.019).Conclusion:Sacubitril/valsartan can significantly improve cardiac function and provide independent protection against MACE in patients with newly diagnosed coronary heart disease.关键词
冠心病/沙库巴曲缬沙坦/血流动力学/心肌功能/主要心血管不良事件Key words
coronary heart disease/sacubitril/valsartan/hemodynamic/myocardial function/major adverse cardiovascular events分类
医药卫生
